Jens-Ulrik S. J.
- Country
- Denmark
- Department
- Lung medication
Research Overview
- COPD - Eosinophil-guided Reduction of Inhaled Corticosteroids (COPERNICOS)
- Evaluation of Live Attenuated Vaccines for Inducing Trained Immunity and Reducing Inflammation in Chronic Obstructive Pulmonary Disease Patients
- Evaluation of Abatacept and Placebo in Hospitalized Adults with COVID-19: A Randomized, Controlled Trial on Immune Modulation Strategies
Data & Insights
Has run more than one trial at 22 of 125 partner sites.
Specializations
Chronic Obstructive Pulmonary Disease and Fibrotic Lung Disease
Clinical activity in COPD, asthma, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and broader interstitial lung disease includes interest in symptom control, exacerbation prevention, and preservation of lung function.
- Inhaled corticosteroid use in COPD
- Astegolimab in COPD
- Inhaled treprostinil in fibrotic lung disease
- BI 1015550 in progressive fibrosing ILD
- Slow-release morphine for breathlessness
Research sites at Rigshospitalet and Gentofte Hospital support work in chronic respiratory disease, including alpha-1 antitrypsin deficiency emphysema and fibrotic interstitial lung disease.
Cardiovascular Disease and Heart Failure
The investigator is involved in studies spanning atherosclerotic cardiovascular disease, heart failure, myocardial infarction, hypertension, and atrial fibrillation, with emphasis on prevention of major adverse cardiovascular events and reduction of thromboembolic risk.
- Inclisiran for cardiovascular risk reduction
- Colchicine in heart failure and vascular inflammation
- Asundexian in atrial fibrillation
- MK-0616 in high cardiovascular risk
- Hydralazine-ISDN and metformin in chronic heart failure
Additional involvement includes cardiac arrest, stroke prevention, and arterial stiffness research in patients with cardiovascular comorbidity.
Inflammatory Skin Disease and Immune-Mediated Disorders
Therapeutic interests extend across atopic dermatitis, chronic hand eczema, hidradenitis suppurativa, chronic spontaneous urticaria, prurigo nodularis, psoriasis, and vitiligo, reflecting a strong focus on inflammatory and pruritic skin conditions.
- Upadacitinib in atopic dermatitis
- Lebrikizumab in moderate-to-severe atopic dermatitis
- Roflumilast in chronic hand eczema
- Lutikizumab in hidradenitis suppurativa
- Barzolvolimab and remibrutinib in chronic spontaneous urticaria
Work in this area also includes nemolizumab for prurigo nodularis and ixekizumab in axial spondyloarthritis and psoriatic arthritis.
Metabolic Disease and Weight Management
Clinical research activity covers obesity, overweight, hypertriglyceridemia, and diabetes-related cardiovascular risk, with attention to cardiometabolic prevention and body-weight reduction.
- CagriSema for obesity
- Orismilast in weight management
- Olezarsen in hypertriglyceridemia
- Colchicine in type 1 diabetes and type 2 diabetes
- Semaglutide-based combination strategies
This portfolio links metabolic treatment to cardiovascular prevention, including studies in patients with established vascular disease and high cardiometabolic risk.
Infectious Disease and Acute Hospital Care
The investigator also contributes to trials in COVID-19, influenza, RSV infection, Gram-negative bacteremia, and Staphylococcus aureus bacteremia, alongside acute inpatient care and perioperative management.
- S-217622 and hyperimmune immunoglobulin for coronavirus infection
- ExPEC9V for invasive Escherichia coli disease
- Antibiotic duration studies in bacteremia
- Sodium bicarbonate in cardiac arrest
- Furosemide for fluid overload in critical care
Further interests include postoperative pain, orthopaedic surgery, and infection prevention in older adults and hospitalized patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.